• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Palliative radiotherapy in bladder cancer - importance of patient selection: a retrospective multicenter study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ali, Adnan
    Song, Yee Pei
    Mehta, Shaveta
    Mistry, H
    Conroy, Ruth
    Coyle, Catherine
    Logue, John P
    Tran, Anna T
    Wylie, James P
    Janjua, T
    Joseph, L
    Joseph, J
    Choudhury, Ananya
    Show allShow less
    Affiliation
    Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M20 4BX, UK
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    OBJECTIVE: Investigate the effectiveness of palliative pelvic radiotherapy (PRT) in bladder cancer patients and identify factors associated with treatment outcome. MATERIAL AND METHODS: Patients with bladder cancer receiving PRT were identified retrospectively from two cancer centres between 2014 and 2017. Patients were stratified by age, stage, performance status, co-morbidities, previous chemotherapy, previous radiotherapy and radiotherapy protocol. Patients were followed up at 6 weeks after RT Median overall survival (mOS) from the last fraction of RT was calculated. Death within 30-days of RT or non-completion of treatment were considered as futile treatment. RESULTS: 241 patients were identified as receiving PRT A variety of RT protocols were used: 8Gy/1 fraction (11%), 21Gy/3 fractions (15%), 20Gy/5 fractions (18%), 36Gy/6 fractions (36%), 27.5-30Gy/8-10 fractions (18%). 38% of patients were of poor performance status (ECOG PS >/=3) and 46.5% had significant co-morbidities (ACE-27 >/=2). The mOS from the last fraction of RT was 153 days (0-1289 days). The 30-day mortality after radiotherapy was 18% (n=44) and incomplete planned radiotherapy treatment was 14% (n=33). First follow up information was available in 62% (n=150) of patients. Median time to this follow-up was 49 days (14-238 days). At first follow up about 6 weeks of last fraction of radiotherapy, patient symptoms were reported in 150 of 200 (75%) alive patients where 80 of 150 (53%) patients reported improvement in symptoms after treatment. There were significant differences in mOS with stage, performance status and co-morbidities. CONCLUSION: One in four patients either did not complete the planned RT course and/or died within 30 days of treatment. These patients were unlikely to have received maximal benefit from treatment but may have experienced side effects, making treatment futile. Patients with good performance status and earlier stage disease survived longer. Patient selection and comprehensive assessment are crucial in selecting appropriate patients for treatment.
    Citation
    Ali A, Song YP, Mehta S, Mistry H, Conroy R, Coyle C, et al. Palliative radiotherapy in bladder cancer - importance of patient selection: a retrospective multicenter study. Int J Radiat Oncol Biol Phys. 2019.
    Journal
    International Journal of Radiation Oncology, Biology, Physics
    URI
    http://hdl.handle.net/10541/622054
    DOI
    10.1016/j.ijrobp.2019.06.2541
    PubMed ID
    31283979
    Additional Links
    https://dx.doi.org/10.1016/j.ijrobp.2019.06.2541
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ijrobp.2019.06.2541
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Clinical radiobiology of stage T2-T3 bladder cancer.
    • Authors: Majewski W, Maciejewski B, Majewski S, Suwinski R, Miszczyk L, Tarnawski R
    • Issue date: 2004 Sep 1
    • Palliative radiation therapy of symptomatic recurrent bladder cancer.
    • Authors: Yi SK, Yoder M, Zaner K, Hirsch AE
    • Issue date: 2007 Mar
    • Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group.
    • Authors: Cox JD, Guse C, Asbell S, Rubin P, Sause WT
    • Issue date: 1988 Dec
    • Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study.
    • Authors: Murthy V, Masodkar R, Kalyani N, Mahantshetty U, Bakshi G, Prakash G, Joshi A, Prabhash K, Ghonge S, Shrivastava S
    • Issue date: 2016 Jan 1
    • Retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma.
    • Authors: Stevens CM, Huang SH, Fung S, Bayley AJ, Cho JB, Cummings BJ, Dawson LA, Hope AJ, Kim JJ, O'Sullivan B, Waldron JN, Ringash J
    • Issue date: 2011 Nov 15
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.